Prometic reports third quarter 2018 financial results and highlights

View our Q3 2018 Quarterly Report

Learn More

Dedicated to the treatment of unmet medical needs in the field of fibrosis and rare orphan diseases.

What we do today will change lives tomorrow.

Learn More

Keep up to date with our latest news

Browse our resources hub for the latest news and information

Learn More

Prometic reports second quarter 2018 financial results and highlights

View our Q2 2018 Quarterly Report

Learn More

About Us

Prometic is a biopharmaceutical corporation with two drug discovery platforms focused on unmet medical needs. The first platform is based on two receptors involved in healing, the second leverages Prometic bioseparation's expertise for the development of plasma derived therapeutics.

Read More

Product Pipeline

Prometic has developed a deep pipeline of late stage clinically active, well tolerated and safe orphan drug candidates targeting unmet medical needs in the field of fibrosis and rare diseases using both its small molecule and plasma derived drug discovery platforms.

Read More

Investors

Why Invest? Prometic has a deep pipeline of drug candidates that are safe and well tolerated with clinically proven activity targeting significant unmet medical needs. Prometic's proprietary drug development platforms enjoy strong IP protection and can generate multiple products.

Read More